Other languages Takeda Pharmaceutical Company Limited Deutsche Boerse AG

Equities

TKDA

US8740602052

Market Closed - Deutsche Boerse AG Other stock markets 02:04:23 2024-06-20 am EDT			5-day change	1st Jan Change
11.6 ^EUR	0.00%		-4.92%	-7.94%

05:59am	Sun Pharma Signs Deal with Japan's Takeda to Commercialize Vonoprazan in India	MT
Jun. 18	Takeda Pharmaceutical Says Results of Phase 3 Trial Support Use of Hyqvia as Maintenance Treatment for CIDP	MT

Other languages

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Sun Pharma Signs Deal with Japan's Takeda to Commercialize Vonoprazan in India	11:59pm
Takeda présente au congrès annuel de la PNS des données à long terme de l’essai clinique ADVANCE-CIDP 3 de Phase 3 portant sur l’administration de HYQVIA® à des patients atteints de polyradiculonévrite inflammatoire démyélinisante chronique (PIDC)	Jun. 19
Takeda presenta datos de largo plazo del ensayo clínico de fase 3 ADVANCE-CIDP 3 de HYQVIA® en pacientes con polineuropatía desmielinizante inflamatoria crónica (PDIC) en la Reunión Anual de la PNS	Jun. 19
Takeda präsentiert Langzeitdaten der klinischen Phase-3-Studie ADVANCE-CIDP 3 mit HYQVIA® bei Patienten mit chronisch entzündlicher demyelinisierender Polyneuropathie (CIDP) auf der PNS-Jahrestagung	Jun. 19
Takeda Pharmaceutical Says Results of Phase 3 Trial Support Use of Hyqvia as Maintenance Treatment for CIDP	Jun. 18
Takeda Announces Data from Phase 3 ADVANCE-CIDP 3 Clinical Trial of HYQVIA in Patients with Chronic Inflammatory Demyelinating Polyneuropathy at PNS Annual Meeting	Jun. 18
Sector Update: Health Care Stocks Decline Premarket Monday	Jun. 17
Ovid Seeks Distance From Epilepsy Drug After Takeda Reports Phase 3 Endpoints Missed -- Pre-Bell Shares Fall	Jun. 17
Takeda Says Phase 3 Soticlestat Trials in Dravet, Lennox-Gastaut Syndromes Missed Primary Endpoints	Jun. 17
Takeda's seizure drug fails to meet main goal in late-stage studies	Jun. 17
Takeda Pharmaceutical Company Limited Announces Topline Data from its Phase 3 SKYLINE and SKYWAY Studies Evaluating Soticlestat for the Treatment of Dravet Syndrome and Lennox-Gastaut Syndrome	Jun. 17
Takeda Announces Phase 3 Topline Results for Soticlestat in Patients with Dravet Syndrome and Lennox-Gastaut Syndrome	Jun. 17
Takeda Signs Option Agreement with Ascentage to License Leukemia Drug	Jun. 14
Takeda Pharmaceutical Company Limited Signs Option Agreement with Ascentage Pharma to Enter into Exclusive Global License for Olverembatinib, Third-Generation BCR-ABL Tyrosine Kinase Inhibitor	Jun. 14
Takeda Pharmaceutical Unit Partners with HEALWELL AI for Real-World Evidence Analysis of Hereditary Angioedema	Jun. 06
Torrent Pharma Signs Deal with Japan's Takeda to Market Acid-Related Disorders Drug in India	Jun. 06
Takeda Pharmaceutical, Pfizer Say Phase 3 Trial Assessing Blood Cancer Combination Therapy Met Co-Primary Endpoints	Jun. 03
Takeda Says Narcolepsy Drug Meets Main, Secondary Goals in Trial	Jun. 03
Takeda Pharmaceutical Company Limited to Present Positive Results from its Phase 2B Trial of TAK-861	Jun. 03
GSK blood cancer drug nearly halves risk of death in late-stage trial	Jun. 02

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Takeda Pharmaceutical Company Limited Deutsche Boerse AG

Equities

TKDA

US8740602052

Other languages

Filters